<code id='2B13EF2503'></code><style id='2B13EF2503'></style>
    • <acronym id='2B13EF2503'></acronym>
      <center id='2B13EF2503'><center id='2B13EF2503'><tfoot id='2B13EF2503'></tfoot></center><abbr id='2B13EF2503'><dir id='2B13EF2503'><tfoot id='2B13EF2503'></tfoot><noframes id='2B13EF2503'>

    • <optgroup id='2B13EF2503'><strike id='2B13EF2503'><sup id='2B13EF2503'></sup></strike><code id='2B13EF2503'></code></optgroup>
        1. <b id='2B13EF2503'><label id='2B13EF2503'><select id='2B13EF2503'><dt id='2B13EF2503'><span id='2B13EF2503'></span></dt></select></label></b><u id='2B13EF2503'></u>
          <i id='2B13EF2503'><strike id='2B13EF2503'><tt id='2B13EF2503'><pre id='2B13EF2503'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:3
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In